ABSTRACT
Background During the first pandemic wave, a substantial decline in mortality was seen among hospitalised COVID-19 patients. We aimed to study if the decreased mortality continued during the second wave, using data compiled by the Swedish National Board of Health and Welfare.
Method Retrospective nationwide observational study of all patients hospitalised in Sweden between March 1st and December 31st, 2020, with SARS-CoV-2 RNA positivity 14 days before to 5 days after admission and a discharge code for COVID-19. Outcome was 60-day all-cause mortality. Poisson regression was used to estimate the relative risk (RR) for death by month of admission, adjusting for age, sex, socio-economic data, comorbidity, care dependency, and country of birth.
Findings A total of 32 452 patients were included. December had the highest number of admissions/month (n=8253) followed by April (n=6430). The 60-day crude mortality decreased from 24·7% (95% CI, 23·0%-26·5%) for March to 10·4% (95% CI, 8·9%-12·1%) for July-September (as reported previously), later increased to 19·9% (95% CI, 19·1-20·8) for December. RR for 60-day death for December (reference) was higher than those for June to November (RR ranging from 0·74 to 0·89; 95% CI <1 for all months). SARS-CoV-2 variants of concern were only sporadically found in Sweden before January 2021.
Interpretation The decreased mortality of hospitalised COVID-19 patients after the first wave turned and increased during the second wave. Focused research is urgent to describe if this increase was caused by a high load of patients, management and treatment, viral properties, or other factors.
Evidence before this study During the first pandemic wave, a substantial decline in mortality was seen among hospitalised COVID-19 patients in many countries. As the reason for this decline has not been clarified, no one could foresee how mortality would change during forthcoming waves.
Added value This retrospective nationwide study of all patients hospitalised for COVID-19 in Sweden from March to December 2020 showed that the gradual decrease in mortality seen in the first pandemic wave was followed by an increased crude and adjusted 60-day all-cause mortality during the second wave. This increase in mortality occurred although the standard-of-care recommendations for hospitalised COVID-19 patients did not change in Sweden during the second half of 2020.
Implications of all the available evidence While improved standard-of-care was believed to be an important factor for the decrease in mortality during the first pandemic wave, the increasing mortality during the second wave has no apparent explanation. As the currently known virus variants of concern occurred only sporadically in Sweden before January 2021, they were most likely not involved. Focused research is urgent to describe if this increase in mortality was caused by a high load of patients, management and treatment factors, viral properties, or other circumstances
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received. As several co-authors are employed by the National Board of Health and Welfare, employees at the funding source contributed to study design, data collection, data analysis, interpretation, and writing of the report. However, no specific funding was designated for the analyses in question. The National Board of Health and Welfare routinely performs epidemiological analyses as part of its mission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the Swedish Ethics Review Authority, Uppsala (Dnr 2020-04278). The study conforms to the Reporting of Observational Studies in Epidemiology (STROBE) statement.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sharing The data underlying this article cannot be shared publicly due to regulations under Swedish law. According to the Swedish Ethics Review Act, the General Data Protection Regulation, the Public Access to Information and Secrecy Act, data can only be made available, after legal review, for researchers who meet the criteria for access to this type of confidential data. Requests regarding data in this paper may be made to the senior author.
